INTRODUCTION
============

The incidence of colorectal cancer has been increasing worldwide \[[@b1-ir-2019-00092]\]. Most colorectal cancers originate from precancerous polyps \[[@b2-ir-2019-00092]\]. Therefore, to decrease mortality, it is extremely important to identify precancerous polyps or early colorectal cancer by routine screening tests and to then treat them to block further development into advanced colorectal cancer. Thus, clinical practice guidelines suggest various screening tests including colonoscopy \[[@b3-ir-2019-00092]-[@b5-ir-2019-00092]\]. Colonoscopy is especially useful due to its ability to detect and treat precancerous polyp and early colorectal cancer \[[@b6-ir-2019-00092]\].

Of early colorectal cancers, superficial submucosal colorectal cancer (SSMC) defined by the depth of invasion from muscularis mucosa as less than 1,000 μm, can be completely cured by endoscopic resection if it does not have any adverse pathologic findings including poorly differentiated adenocarcinoma and lymphovascular invasion or tumor budding \[[@b7-ir-2019-00092]-[@b11-ir-2019-00092]\]. If these indications are followed, there is no difference in longterm outcomes between endoscopic resection and surgery in SSMC \[[@b12-ir-2019-00092]\]. In situations where a deep submucosal cancer (DSMC) with a depth of more than 1,000 μm, poor pathologic prognostic features such as poor differentiation or lymphovascular invasion, and presence of positive resection margin, the possibility of regional node involvement or residual cancer cannot be ruled out, so it is recommended to add surgery to remove the residual cancer or regional lymph nodes involved by cancer \[[@b13-ir-2019-00092]\].

To minimize the need for additional surgery, accurately estimating whether the early cancer is either SSMC or DSMC is crucial because the SSMC requires only endoscopic resection, while DSMC is treated by surgery. Endoscopic observation including dye chromoscopy and image enhanced endoscopy such as narrow band imaging (NBI) is used to identify the possibility of SSMC or DSMC before endoscopic resection \[[@b14-ir-2019-00092]-[@b17-ir-2019-00092]\]. Despite these various examination methods, it is not uncommon that lesions initially predicted as SSMC is ultimately diagnosed as DSMC and/or cancer with poor pathologic prognostic features after endoscopic resection thereby necessitating additional surgery \[[@b18-ir-2019-00092]\]. Furthermore, it is also not uncommon that surgical specimens of DSMC and/or cancer with poor pathologic features show no regional lymph metastasis nor residual cancer thereby raising a question whether additional surgery would have been really necessary.

Our study aimed to investigate the frequency of receiving surgery after endoscopic resection of suspected SSMC by analyzing the pathological diagnosis of the endoscopically resected specimen. We also aimed to evaluate the frequency and risk factors of regional lymph node metastasis or residual cancer in surgical specimens by reviewing the pathology reports. Furthermore, we tried to validate the overall long-term prognosis of presumed SSMC that is treated by endoscopic resection.

METHODS
=======

1. Patients
-----------

From June 1996 to June 2015, we retrospectively reviewed the medical records of patients at Asan Medical Center who underwent endoscopic resection for T1 early cancer initially presumed as SSMC, followed by endoscopy, abdominal pelvic CT and chest radiography imaging. We presumed a tumor as suspected SSMC if the tumor showed type VI Kudo pit pattern and/or JNET (Japan NBI Expert Team) 2B NBI pattern without definite evidence of deep ulcer and non-lifting sign. A suspected SSMC assessed by these endoscopic features was managed initially by endoscopic resection. The following patients were excluded: (1) patients who had at least one previous colorectal cancer; (2) patients with cancers in other sites in addition to colorectum; (3) patients who underwent endoscopic resection followed by transanal surgical resection or radiation therapy; (4) patients without pathological reports because treatment occurred at outside hospital; and (5) patients with follow-up of less than 1 year after the procedure. This study was conducted with the approval of the Institutional Review Board of Asan Medical Center in Seoul (IRB No. 2016-0085). This study is a retrospective study using medical record review and so informed consent was waived.

2. Endoscopic Resection
-----------------------

Endoscopic resection for all SSMC lesions was performed by board-certified GI endoscopists who were highly specialized for therapeutic colonoscopy procedures. SSMC was estimated by white light endoscopy and examination of pit pattern through chromoscopy after indigocarmine spray. From 2008 onwards, analysis of the surface vascular pattern using NBI has been helpful for estimating the presence of SSMC. Endoscopic mucosal resection and/or endoscopic submucosal dissection were used, depending on the location, shape, and size of the lesion. *En bloc* resection was tried whenever possible. Lesion location was classified as proximal colon, distal colon, or rectum. Proximal colon included the cecum, ascending colon, hepatic flexure, and transverse colon; and the distal colon included splenic flexure, descending colon, and sigmoid colon.

3. Histopathological Review and Additional Surgery
--------------------------------------------------

Histopathologic examination of endoscopic resection specimens was used to determine invasion depth of cancer, differentiation, lymphovascular invasion, and status of lateral and deep resection margins. (1) DSMC (depth of submucosal cancer invasion ≥ 1,000 μm or SM2 or SM3), (2) positive lymphovascular invasion, and (3) poorly differentiated adenocarcinoma, signet ring cell carcinoma, or mucinous carcinoma, (4) positive or indeterminate resection margins were defined as high-risk pathological features according to Japanese Society for Cancer of the Colon and Rectum and European Society of Gastrointestinal Endoscopy guidelines. In the present study, perineural invasion was also defined as high-risk pathology \[[@b19-ir-2019-00092],[@b20-ir-2019-00092]\]. Patients who showed endoscopic resection specimens with any of the highrisk pathologic findings were recommended to undergo surgical resection with lymph node dissection. In some cases of SSMC without high-risk findings, surgery was also performed depending on the preference of patients and medical staff.

After surgery, histopathologic examination of the surgical specimens was used to confirm the presence of residual cancer in the endoscopic resection site and regional lymph node involvement.

4. Review of Clinical Course
----------------------------

Patients' medical records were reviewed retrospectively. The starting point of follow-up was the time of endoscopic resection, and the patient's age was the age at the time of endoscopic resection. We reviewed follow-up medical records until September 2017, including endoscopic, abdominopelvic CT and chest radiography results. Through this, we identified recurrence and death. Recurrence-free survival was defined as the time from the endoscopic resection until the confirmation of colorectal cancer recurrence. Recurrence was classified as local and metastatic recurrence. Local recurrence was defined as recurrence at the previous endoscopic resection site, as confirmed by endoscopic biopsy. Metastatic recurrence was defined as lymph node metastasis and/or metastasis to distant organs such as liver, lung, and peritoneum. Overall survival was defined as the time until the confirmation of death after endoscopic resection.

5. Statistical Analysis
-----------------------

Continuous variables were analyzed using Student *t*-test or Mann-Whitney *U*-test. Categorical parameters were compared using the chi-square test or Fisher exact test. To examine independent risk factors, logistic regression was used. Variables that were statistically and clinically significant in the univariate analysis were included in the multivariate analysis. Cumulative overall and recurrence-free survival rates were analyzed with the Kaplan--Meier method. Comparisons of overall and recurrence-free survival rates were performed with the log rank test. *P*\< 0.05 in a two-sided test was considered statistically significant. All these statistical analyses were performed by the R version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria; <https://www.r-project.org/>).

RESULTS
=======

1. Baseline Characteristics
---------------------------

The mean age of the 497 patients included in the study was 58.8 years old and 331 (66.6%) were male. The mean size of early colorectal cancer in which SSMC was suspected was 19.3 ± 10.8 mm ([Table 1](#t1-ir-2019-00092){ref-type="table"}). Endoscopic mucosal resection was performed in 393 patients (79.1%) and endoscopic submucosal dissection was performed in 104 patients (20.9%). *En bloc* resection was performed in 447 patients (89.9%) and piecemeal resection was performed in 50 patients (10.1%).

When endoscopic resection specimens were examined, 173 patients (34.8%) had submucosal invasion depth \< 1,000 μm of cancer. Well differentiated adenocarcinoma was identified in 235 patients (47.3%) and poorly differentiated adenocarcinoma was identified in 7 patients (1.4%). Positive lymphovascular invasion was observed in 72 patients (14.5%). Positive cancer involvement in the lateral resection margin was identified in 40 patients (8.0%) and 70 patients (14.1%) had positive cancer involvement in the deep resection margin. As a result, 372 (74.8%) had one or more high-risk pathological features. Of the 372 patients with high-risk pathological features, 336 underwent surgery and 27 of 125 patients without high-risk pathological features also underwent surgery ([Fig. 1](#f1-ir-2019-00092){ref-type="fig"}). There was no patient who underwent secondary endoscopic treatment in the group with high-risk pathology features.

2. Clinical Outcomes during the Follow-up Period
------------------------------------------------

The mean follow-up period was 91.9 ± 39.7 months (range, 27--255 months) after endoscopic resection. Six out of 497 patients (1.2%) had recurrence during the follow-up period. None out of 15 cecal lesions (0%) showed recurrence. Recurrence developed in 1 (2.1%) of 48 ascending colonic lesions, 0 (0%) of 44 transverse colonic lesions, 1 (3.1%) of 32 descending colonic lesions, 2 (1.0%) of 203 sigmoid colonic lesions, and 2 (1.3%) of 152 rectal lesions. Among the 98 patients without high-risk pathological features who did not undergo surgery, 1 patient (0.8%) had recurrence. The patient had been treated not by *en bloc* resection but by piecemeal resection, and local recurrence of benign adenoma was confirmed during follow-up colonoscopy 7 months after endoscopic piecemeal resection ([Table 2](#t2-ir-2019-00092){ref-type="table"}). No recurrence developed in 27 of 125 patients without high-risk features who underwent additional surgery because of patients' request based on their fear for cancer recurrence ([Fig. 1](#f1-ir-2019-00092){ref-type="fig"}). Among 372 patients with highrisk pathological features, 36 patients did not undergo surgery because of old age, underlying diseases, and fear for surgery. One of the 36 patients (2.8%) had recurrence. Four out of 336 patients (1.2%) who underwent surgery had recurrence.

There was no statistically significant difference in recurrence-free survival and overall survival among the 4 groups according to the presence of high-risk pathological features and performance of additional surgery ([Figs. 2](#f2-ir-2019-00092){ref-type="fig"}, [3](#f3-ir-2019-00092){ref-type="fig"}).

3. Analysis of Additional Surgical Resection Specimen
-----------------------------------------------------

Of the 125 patients without high-risk pathological features, no residual cancer or regional lymph node metastasis was found among the 27 surgically treated patients.

There were 19 patients (5.7%) with residual cancer at the endoscopic resection site and 32 patients (9.5%) with regional lymph node metastasis out of 336 surgically treated cases with high-risk pathological features. Four out of these of 336 patients surgically treated with high-risk pathological features had both the residual cancer and the regional lymph node metastasis, resulting in residual cancer or regional lymph node metastasis in 47 (14.0%) of the 336 cases, and 289 (86.0%) with no regional lymph node metastasis and residual cancer ([Fig. 1](#f1-ir-2019-00092){ref-type="fig"}). Piecemeal resection, positive lateral resection margin, and positive deep resection margin were more frequent in patients with residual cancer or regional lymph node metastasis (9/47 \[19.1%\] vs. 24/289 \[8.3%\], *P*= 0.032; 11/47 \[23.4%\] vs. 29/289 \[10.0%\], *P*= 0.035; 18/47 \[38.3%\] vs. 52/289 \[18.0%\] *P*= 0.001, respectively) ([Table 3](#t3-ir-2019-00092){ref-type="table"}). Positive deep resection margin was also a risk factor for residual cancer and regional lymph node metastasis each, respectively (detailed data not shown).

Regional lymph node metastasis was detected in 32 cases (8.8%) of 363 patients undergoing additional surgery. We analyzed the risk of regional lymph node metastasis after additional surgery depending on the number of high-risk pathological features in endoscopic resection specimens. The risk of regional lymph node metastasis also increased as the number of high-risk pathological features increased (*P* for trend = 0.002) ([Table 4](#t4-ir-2019-00092){ref-type="table"}).

DISCUSSION
==========

In this large-scale study, which reviewed the specimens of endoscopic resection of 497 patients who were initially diagnosed with SSMC and then analyzed the long-term follow-up patient outcomes, 6 patients recurred during the mean followup period of 91.9 months with the recurrence rate of 1.2%, reassuring the excellence of endoscopic treatment. Of the 125 patients without high-risk pathological features, only 1 local recurrence, of benign adenoma, was seen. Among patients with high-risk pathological features, 5 (1.3%) distant metastatic recurrences were identified. Only 47 (14.0%) of the 336 patients with high-risk pathological features who underwent surgery were found of residual cancer or regional lymph node metastasis. There was a high risk of residual cancer or regional lymph node metastasis in surgical specimens when piecemeal resection was performed or endoscopic resection specimen showed cancer involvement at the resection margin. In addition, interestingly, we found that the risk of regional lymph node metastasis increased proportionally as the number of high-risk pathological features increased in endoscopic resection specimens, which is a novel finding of our study.

Previous studies examining the clinical course after the treatment of early colorectal cancer reported recurrence rates of 0%--2.3% after endoscopic resection for low-risk T1 cancers, 4.4%--20% after endoscopic resection for high-risk T1 cancer, and 1.4%--5.6% after surgical resection for high-risk T1 cancer \[[@b12-ir-2019-00092],[@b21-ir-2019-00092]-[@b26-ir-2019-00092]\]. In our study, which investigated the patients who underwent endoscopic resection at first with the estimation of SSMC the overall recurrence rate was 1.2%. The recurrence rate was 0.8% in the low-risk group (1/125), and 1.2% in the high-risk group with additional surgery, similar with that of the previous studies. In our study, the recurrence rate of 2.8% in the high-risk group with endoscopic resection and without surgical resection was slightly lower than that of the previous study, owing to the small number of patients in this group, being only 36.

The reported recurrence rate after endoscopic resection of high-risk submucosal cancer is not so low as 4.4%--20% unless surgery is performed. Additional surgery is therefore recommended \[[@b12-ir-2019-00092],[@b13-ir-2019-00092],[@b21-ir-2019-00092]-[@b27-ir-2019-00092]\]. However, residual cancer or regional lymph node metastasis is not always found in surgical specimens after additional surgery. In our study, residual cancer and/or regional lymph node metastasis were found only in 47 (14.0%) of 336 surgically performed cases due to high-risk pathological features. This finding suggests that even with high-risk pathological features in endoscopic resection specimens, 86% of patients had no residual lesions and therefore may not need to undergo additional surgery. Thus, we suggest that if patients with high-risk pathological features can be categorized into patients with a high risk of residual cancer or regional lymph node metastasis by the more accurate method clarified through further study, this may be ideal for more effective surgery. In our study, piecemeal resection and cancer involvement at the resection margins were significantly associated with residual cancer or regional lymph node metastasis identified in surgical specimens. Piecemeal resection has a high risk of incomplete resection and is likely to leave residual lesions. In fact, the local recurrence rate after piecemeal resection for a large colorectal neoplasm has been reported to be 0%--55% \[[@b28-ir-2019-00092]-[@b31-ir-2019-00092]\]. In addition, positive resection margins are also suggestive of residual lesions, and piecemeal resection and positive resection margins suggest that lesions are large and invasion depth of cancer is considerably deep. Large, deeply invasive cancers are more likely to have regional lymph node metastasis \[[@b7-ir-2019-00092],[@b9-ir-2019-00092],[@b32-ir-2019-00092],[@b33-ir-2019-00092]\]; therefore, if endoscopic resection is performed because of suspected SSMC and high-risk pathological features are seen in the resected specimen, additional surgery should be performed. However, if it is difficult to decide to perform additional surgery due to such reasons as comorbidity and old age, strategies for further active surgery can be considered cautiously in cases with additional risk factors such as piecemeal resection and/or positive resection margin.

In several studies of pathologic risk factors predicting regional lymph node metastasis, some high-risk pathological features such as lymphovascular invasion have been reported to have a greater impact on metastasis than other factors, such as poor differentiation \[[@b13-ir-2019-00092],[@b34-ir-2019-00092],[@b35-ir-2019-00092]\]. On the other hand, the number as well as characteristics of pathological risk factors may be associated with regional lymph node metastasis risk. Backes et al. \[[@b36-ir-2019-00092]\] developed the LASSO (Least Absolute Shrinkage and Selection Operator) model to calculate the probability of pedunculated T1 cancer metastasis by inputting the presence or absence of various pathologic risk factors. Our study also confirmed a positive correlation in the risk of regional lymph node metastasis as the number of high-risk pathological features increased. Therefore, if multiple high-risk pathological features are found after endoscopic resection with suspicion of SSMC, it is advisable to recommend additional surgery more strongly than if one has a single high-risk pathological feature. We think that it is necessary to carry out a large-scale multicenter study in order to estimate the regional lymph node metastasis risk according to the number of high-risk pathological features. In addition, such large, multicenter studies may establish a reliable predictive model incorporating not only pathological risk features but also technical features related to endoscopic procedures, which can predict the risk of residual cancer and/or lymph node metastasis with high accuracy.

In the present study, 51.1% of suspected SSMC were actually DSMC ([Table 1](#t1-ir-2019-00092){ref-type="table"}). We suggest endoscopic prediction of SSMC was not accurate although we used NBI and/or chromoscopy to assess the invasion depth. We also suggest there could be possible overuse of endoscopic resection in cases which were not considered as SSMC with high confidence. Further effort to assess the invasion depth precisely before endoscopic resection should be made to avoid unnecessary surgery.

Our study has several limitations. First, not all patients had formalized follow-up schedules and follow-up examinations, and some patients did not reach a 5-year follow-up period to determine whether they are cured. Second, there is a difference in endoscopy models and ancillary apparatus types because the period of registration extended from 1996 to 2015. Furthermore, endoscopic pictures were absent in some old cases and we could not investigate the morphology (pedunculated vs. sessile vs. flat) of suspected SSMC cases. Therefore, we could not analyze the recurrence rate according to cancer morphology. Third, submucosal invasion depth of cancer was pathologically diagnosed as SM1, SM2, and SM3 until the mid 2000s, whereas, since the late 2000s, it was diagnosed using absolute measurements. Likewise, we could not investigate tumor budding status in this study because the importance of tumor budding was not introduced widely in clinical practice in late 1990s and early 2000s. Fourth, although total number of patients was high, numbers of patients with each high-risk pathological feature and residual cancer in surgical specimen were small (poorly differentiated adenocarcinoma only in 2 \[4.3%\] and perineural invasion in 0 \[0%\] surgical specimen). This could be made the results negative. In addition, the small number of recurred cases may also have made identification of reliable risk factors difficult. Despite these limitations, we believe that our study shows the clinical reality of high-risk pathological features found after endoscopic resection of suspected SSMC and the frequency which residual cancer or lymph node metastasis is found in the patients with high-risk pathological features who underwent surgery after endoscopic resection.

In conclusion, residual cancer or regional lymph node metastasis was present in 14.0% of the cases undergoing surgery because of the high-risk pathological features. Conversely, in 86.0% of patients, residual cancer or regional lymph node metastasis was not seen, raising a question about whether surgery would have been necessary. Nonetheless, currently, additional surgery should be performed in patients whose surgical specimen shows high-risk pathological features because there are no better predictive methods for remnant cancer than the histological findings of surgical specimen and the surgical mortality of elective colectomy is only about 1%. Further large, multicenter studies on other predictors of residual lesions are necessary for establishing optimized strategies to quantify and validate the risk of residual lesions.
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###### 

Baseline Characteristics of Patients

  Variable                                                   Value (n = 497)
  ---------------------------------------------------------- -----------------
  Age (yr)                                                   58.8 ± 9.8
  Sex                                                        
   Male                                                      331 (66.6)
   Female                                                    166 (33.4)
  Tumor size (mm)                                            19.3 ± 10.8
  Tumor location                                             
   Proximal                                                  107 (21.5)
   Distal                                                    235 (47.3)
   Rectum                                                    152 (30.6)
   Indeterminate                                             3 (0.6)
  Resection modality                                         
   EMR                                                       393 (79.1)
   ESD                                                       104 (20.9)
  Resection method                                           
   *En bloc*                                                 447 (89.9)
   Piecemeal                                                 50 (10.1)
  Pathological features of resected specimen                 
   Invasion depth of cancer                                  
    SM \< 1,000 μm                                           173 (34.8)
    SM ≥ 1,000 μm                                            254 (51.1)
    SM, unknown                                              70 (14.1)
   Differentiation                                           
    Well                                                     235 (47.3)
    Moderate                                                 254 (51.1)
    Poor                                                     7 (1.4)
    Unknown                                                  1 (0.2)
   Lymphovascular invasion                                   
    Negative                                                 392 (78.9)
    Positive                                                 72 (14.5)
    Unknown                                                  33 (6.6)
   Perineural invasion                                       
    Negative                                                 357 (71.8)
    Positive                                                 5 (1.0)
    Unknown                                                  135 (27.2)
   Lateral resection margin                                  
    Negative                                                 415 (83.5)
    Cancer                                                   40 (8.0)
    Indeterminate                                            42 (8.5)
   Deep resection margin                                     
    Negative                                                 391 (78.7)
    Cancer                                                   70 (14.1)
    Indeterminate                                            36 (7.2)
  High-risk pathology in the endoscopic resection specimen   
   Absent                                                    125 (25.2)
   Present                                                   372 (74.8)

Values are presented as mean±SD or number (%).

EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; SM, submucosa.

###### 

Clinical Features of Recurrence Cases

  Case   Sex/age (yr)   Location     Size (mm)   Resection modality   Resection method   No. of high-risk pathological features   Additional surgery            Time to recurrence (mon)   Type of recurrence                                                  Treatment for recurrence
  ------ -------------- ------------ ----------- -------------------- ------------------ ---------------------------------------- ----------------------------- -------------------------- ------------------------------------------------------------------- -------------------------------------------
  A      M/64           Sigmoid      13          EMR                  Piecemeal          0                                        No                            7                          Local recurrence at endoscopic resection site                       Re-endoscopic resection
  B      M/48           Descending   35          EMR                  *En bloc*          1 (LVI)                                  No                            40                         Metastatic recurrence at distant lymph nodes                        Surgery + chemotherapy
  C      M/60           Sigmoid      18          EMR                  Piecemeal          3 (DSMC, DRM, LRM)                       Yes, anterior resection       48                         Metastatic recurrence at lung                                       Surgery
  D      M/54           Rectum       12          ESD                  *En bloc*          4 (DSMC, DRM, LVI, PNI)                  Yes, low anterior resection   6                          Metastatic recurrence at liver                                      Surgery and chemotherapy
  E      M/69           Ascending    11          EMR                  *En bloc*          4 (DSMC, DRM, LRM, LVI)                  Yes, right hemicolectomy      33                         Metastatic recurrence at anastomosis site and adjacent peritoneum   Chemotherapy
  F      M/60           Rectum       9           EMR                  *En bloc*          3 (DSMC, DRM, LRM)                       Yes, low anterior resection   89                         Metastatic recurrence at lung and brain                             Gamma knife radiosurgery and chemotherapy

M, male; F, female; EMR, endoscopic mucosal resection; LVI, lymphovascular invasion (+); DSMC, deep submucosal cancer; DRM, deep resection margin involvement (+); LRM, lateral resection margin involvement (+); ESD, endoscopic submucosal dissection; PNI, perineural invasion involvement (+).

###### 

Comparison between Cases with Residual Cancer and/or Positive Regional Lymph Nodes in the Surgical Specimen and Those Without

  Variable                                     Residual cancer and/or positive regional lymph nodes in the surgical specimen   *P*-value     
  -------------------------------------------- ------------------------------------------------------------------------------- ------------- ----------
  Age (yr)                                     57.8 ± 9.3                                                                      58.8 ± 9.5    0.505
  Sex                                                                                                                                        \> 0.999
   Male                                        188 (65.1)                                                                      30 (63.8)     
   Female                                      101 (34.9)                                                                      17 (36.2)     
  Tumor size (mm)                              18.9 ± 11.6                                                                     20.4 ± 11.2   0.504
  Tumor location                                                                                                                             0.479
   Proximal                                    69 (23.9)                                                                       8 (17.0)      
   Distal                                      141 (48.8)                                                                      23 (48.9)     
   Rectum                                      79 (27.3)                                                                       16 (34.0)     
  Resection modality                                                                                                                         0.226
   EMR                                         238 (82.4)                                                                      35 (74.5)     
   ESD                                         51 (17.6)                                                                       12 (25.5)     
  Resection method                                                                                                                           0.032
   *En bloc*                                   265 (91.7)                                                                      38 (80.9)     
   Piecemeal                                   24 (8.3)                                                                        9 (19.1)      
  Pathological features of resected specimen                                                                                                 
   Invasion depth of cancer                                                                                                                  0.299
    SM \< 1,000 μm                             34 (11.8)                                                                       4 (8.5)       
    SM ≥ 1,000 μm                              202 (69.9)                                                                      30 (63.8)     
    SM, unknown                                53 (18.3)                                                                       13 (27.7)     
   Differentiation                                                                                                                           0.220
    Well                                       125 (43.3)                                                                      16 (34.0)     
    Moderate                                   159 (55.0)                                                                      29 (61.7)     
    Poor                                       5 (1.7)                                                                         2 (4.3)       
   Lymphovascular invasion                                                                                                                   0.656
    Negative                                   208 (72.0)                                                                      31 (66.0)     
    Positive                                   57 (19.7)                                                                       11 (23.4)     
    Unknown                                    24 (8.3)                                                                        5 (10.6)      
   Perineural invasion                                                                                                                       \> 0.999
    Negative                                   179 (61.9)                                                                      30 (63.8)     
    Positive                                   5 (1.7)                                                                         0             
    Unknown                                    105 (36.3)                                                                      17 (36.2)     
   Lateral resection margin                                                                                                                  0.035
    Negative                                   228 (78.9)                                                                      31 (66.0)     
    Cancer                                     29 (10.0)                                                                       11 (23.4)     
    Indeterminate                              32 (11.1)                                                                       5 (10.6)      
   Deep resection margin                                                                                                                     0.001
    Negative                                   212 (73.4)                                                                      22 (46.8)     
    Cancer                                     52 (18.0)                                                                       18 (38.3)     
    Indeterminate                              25 (8.7)                                                                        7 (14.9)      

Values are presented as mean±SD or number (%).

EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; SM, submucosa.

###### 

Association between the Number of High-Risk Pathological Features and the Risk of Regional Lymph Node Metastasis

  No. of high-risk pathological features   Regional lymph node metastasis   *P* for trend   
  ---------------------------------------- -------------------------------- --------------- -------
  0                                        1 (3.0)                          32 (97.0)       0.002
  1                                        9 (4.9)                          173 (95.1)      
  2                                        11 (14.5)                        65 (85.5)       
  3                                        10 (15.4)                        55 (84.6)       
  4                                        1 (14.3)                         6 (85.7)        

Values are presented as number (%). List of high-risk pathological features: invasion depth, differentiation, deep resection margin, lateral resection margin, lymphovascular invasion, perineural invasion.
